Corient Private Wealth
STOK icon

Corient Private Wealth’s Stoke Therapeutics STOK Stock Holding History

Corient Private Wealth’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.01M Buy
+30,823
New +$989K ﹤0.01% 1811
2025
Q3 		– Sell
-659,834
Closed -$7.49M – 2676
2025
Q2 		$7.49M Buy
+659,834
New +$6.26M 0.01% 593

Other funds holding STOK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Corient Private Wealth's STOK Position: Q2 2026 in Review

Corient Private Wealth opened a new position in Stoke Therapeutics (STOK) in Q2 2026: 30,823 shares worth $1.01M. The stake represents ﹤0.01% of the portfolio and ranks #1811 among its holdings. This is a return to the name: Corient Private Wealth previously reported a position in STOK as recently as Q2 2025.

Corient Private Wealth first reported a position in STOK in Q2 2025 and has held it in 2 quarters since. The position peaked at $7.49M in Q2 2025. 197 funds tracked by Wall St. Rank hold STOK as of Q2 2026.

  • Corient Private Wealth held 30,823 shares of Stoke Therapeutics worth $1.01M as of Q2 2026.
  • Stoke Therapeutics was a new Corient Private Wealth position in Q2 2026.
  • Stoke Therapeutics made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1811 holding.
  • Corient Private Wealth first reported a position in Stoke Therapeutics in Q2 2025 and has held it in 2 quarters since.
  • Corient Private Wealth's Stoke Therapeutics position peaked at $7.49M in Q2 2025.
  • 197 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.